Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bimekizumab dose study in adolescents with moderate to severe plaque psoriasis
2023-509832-24-00Phase 2Completed
- Sponsor
- UCB
- Start
- Apr 2024
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 4
01
Overview
Phase 2, randomised, open-label trial of bimekizumab in plaque psoriasis (2 arms), sponsored by UCB. Primary endpoints: Plasma concentration of bimekizumab at Week 0, Plasma concentration of bimekizumab at Week 1 and 12 more. Started Apr 2024; status: completed.
02
Drugs
bimekizumab
03
Conditions
plaque psoriasis
Beyond the preview
Go deeper on 2023-509832-24-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-509832-24-00.